These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32854442)

  • 1. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
    Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
    Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
    Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
    Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs).
    Long YX; Sun Y; Liu RZ; Zhang MY; Zhao J; Wang YQ; Zhou YW; Cheng K; Chen Y; Zhu CR; Liu JY
    Curr Oncol; 2022 Jan; 29(1):267-282. PubMed ID: 35049699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.
    Teng F; Li M; Yu J
    BMC Med; 2020 Sep; 18(1):275. PubMed ID: 32943072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
    Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
    Yin J; Wu Y; Yang X; Gan L; Xue J
    Front Immunol; 2022; 13():830631. PubMed ID: 35464480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade.
    Nardone V; Giannicola R; Bianco G; Giannarelli D; Tini P; Pastina P; Falzea AC; Macheda S; Caraglia M; Luce A; Zappavigna S; Mutti L; Pirtoli L; Giordano A; Correale P
    Front Oncol; 2021; 11():684110. PubMed ID: 34195086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.
    Nardone V; Giannicola R; Giannarelli D; Saladino RE; Azzarello D; Romeo C; Bianco G; Rizzo MR; Di Meo I; Nesci A; Pastina P; Falzea AC; Caracciolo D; Reginelli A; Caraglia M; Luce A; Mutti L; Giordano A; Cappabianca S; Pirtoli L; Barbieri V; Tassone P; Tagliaferri P; Correale P
    Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer.
    Hall KH; Liu Y; Jiang C; Harvey RD
    Pharmacotherapy; 2020 Feb; 40(2):133-141. PubMed ID: 31863604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study.
    Zhukova N; Orlova R; Malkova A; Kaledina E; Demchenkova A; Naimushina P; Nazarov V; Mazing A; Lapin S; Belyak N; Shoenfeld Y
    Crit Rev Immunol; 2022; 42(3):1-9. PubMed ID: 37017622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.